title: Molecular Response of e19a2 BCR-ABL1 Chronic Myeloid Leukemia With Double Philadelphia Chromosome to Dasatinib.
authors.affiliation: Fukushima Medical University, Fukushima, Japan kazu-ike@fmu.ac.jp.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Ikeda
authors.affiliation: Fukushima Medical University, Fukushima, Japan.
authors.forename: Kayo
authors.initials: K
authors.lastname: Harada-Shirado
authors.affiliation: Fukushima Medical University, Fukushima, Japan.
authors.forename: Hayato
authors.initials: H
authors.lastname: Matsumoto
authors.affiliation: Fukushima Medical University, Fukushima, Japan.
authors.forename: Hideyoshi
authors.initials: H
authors.lastname: Noji
authors.affiliation: Fukushima Medical University, Fukushima, Japan.
authors.forename: Kazuei
authors.initials: K
authors.lastname: Ogawa
authors.affiliation: Fukushima Medical University, Fukushima, Japan.
authors.forename: Yasuchika
authors.initials: Y
authors.lastname: Takeishi
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000069439:Dasatinib / Q000627:therapeutic use*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D010677:Philadelphia Chromosome; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib